In EZH2-mut AML patients, co-occurring mutations were most frequently found in CEBPA (4/6, 67%), ASXL1 (3/6, 50%), TET2, and RAD21 (2/6, 33% each). Here, RAD21 is linked to acute myeloid leukemia.